Related Experiment Video
Updated: Jun 2, 2026
15:48
ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
Published on: July 29, 2007
[Development of new therapies for multiple sclerosis]
Trygve Holmøy1, Elisabeth Gulowsen Celius
1Nevrologisk avdeling, Oslo universitetssykehus, Ullevål ogImmunologisk institutt, Universitetet i Oslo, Norway. trygve.holmoy@rr-research.no
Summary
New multiple sclerosis (MS) treatments, including monoclonal antibodies and oral agents, show promise for relapsing-remitting MS but carry risks. Further research is needed to clarify indications for these emerging therapies.
Area of Science:
- Neurology
- Immunology
- Pharmacology
Background:
- Current first-line treatments for multiple sclerosis (MS) exhibit moderate efficacy and significant side effects.
- There is a need for more effective and tolerable MS therapies.
Purpose of the Study:
- To review emerging drug opportunities and challenges in multiple sclerosis treatment.
- To evaluate the potential of novel therapeutic agents for MS.
Main Methods:
- A non-systematic literature search was conducted using PubMed and congress abstracts.
- Key studies on novel MS therapies were identified and analyzed.
Main Results:
- Monoclonal antibodies (e.g., natalizumab, alemtuzumab, rituximab, daclizumab) and oral agents (e.g., fingolimod, cladribine) target key pathways in MS immunopathogenesis.
- These novel agents demonstrate considerable efficacy in relapsing-remitting MS but are associated with serious adverse events.
- Natalizumab is approved for both second-line and, in severe cases, first-line treatment of relapsing-remitting MS.
Conclusions:
- The treatment landscape for multiple sclerosis exacerbations is evolving with new therapeutic options.
- The precise indications and long-term safety profiles for these developing drugs require further clarification.
Related Concept Videos
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:28Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
01:26Drug Administration and Therapy Phases: Overview
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...